PubMed Health⌕ Search

Biomedical subjects

Matt Stevenson

Publications and source records attributed to Matt Stevenson.

2 recordsLinked to original sources

Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.

Probabilistic sensitivity analysis (PSA) is required to account for uncertainty in cost-effectiveness calculations arising from health economic models. The simplest way to perform PSA in practice is by Monte Carlo methods, which involves running the model many times using randomly sampled values of the model inputs. However, this can be impractical when the economic model takes appreciable amounts of time to run. This situation arises, in particular, for patient-level simulation models (also known as micro-simulation or individual-level simulation models), where a single run of the model simulates the health care of many thousands of individual patients. The large number of patients required in each run to achieve accurate estimation of cost-effectiveness means that only a relatively small number of runs is possible. For this reason, it is often said that PSA is not practical for patient-level models. We develop a way to reduce the computational burden of Monte Carlo PSA for patient-level models, based on the algebra of analysis of variance. Methods are presented to estimate the mean and variance of the model output, with formulae for determining optimal sample sizes. The methods are simple to apply and will typically reduce the computational demand very substantially.

Analysis of Variance↗

Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule.

This work estimates the health and cost impacts of a pre-school booster vaccination for Bordetella pertussis, when added to existing UK primary vaccination. A transition state simulation model of pertussis infection in a closed population was constructed comprising of susceptible, infected and immune population sub-groups, across eight age bands. Epidemiological, service use and cost data were sourced from routine statistics, published literature and clinician estimates. The introduction of a pre-school booster is predicted to reduce the number of hospitalisations by approximately 1400 and pertussis cases suffered by up to 28,000 at a net investment of under 13 million pounds over a 5-year period.

Child, Preschool↗